Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

From single neuron to brain: multi-level strategy and digital twins for personalized prediction of treatment

Objectif

Epilepsy is a common neurological disorder characterized by recurrent seizures. Treatment is typically trial-and-error and may take years before seizure control is achieved. The pathophysiology of epilepsy is poorly understood and the clinical diversity is striking. This makes it difficult to predict how a patient will respond to medication, which poses major challenges for treatment prognosis.
The advent of human induced pluripotent stem cells allowed the phenotype, molecular abnormalities, and drug responses of epilepsy to be investigated in vitro in a patient-specific manner. However, little is known about how to translate these in vitro findings to humans, so there is a big gap between clinical practice and research in epilepsy.
The main goal of this project is to close that gap – to enhance the prediction of personalized treatment in epilepsy by translating findings from in vitro models to patients. To achieve this, I will develop a multi-level strategy “from neuron, to network, to brain”, in which clinical features, neuronal network phenotypes, and single-cell abnormalities can be studied for individual patients. I will characterize the phenotype and response to medication at these different levels of complexity and will use digital twin approaches to bridge the information between the levels by unraveling cellular mechanisms underlying network and brain dynamics. For each individual patient, I will identify biomarkers for treatment prediction by defining the cellular mechanisms that correlate at the different levels. This approach will show how relevant in vitro findings are to patients. It ultimately will allow individual phenotypes to be investigated and treatment efficacy to be estimated in vitro, with a reliable translation of findings to the patient. If successful, this bioengineering tool will help to reduce the burden of drug screening for patients and will significantly improve treatment.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-STG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

UNIVERSITA DEGLI STUDI DI GENOVA
Contribution nette de l'UE
€ 1 250 000,00
Coût total
€ 1 250 000,00

Bénéficiaires (2)